FrieslandCampina Ingredients is expanding its lactoferrin production capacity in its Veghel facility by 60 metric tons in 2022 to expand its early life nutrition and adult nutrition segments.
Photo © stock.adobe.com/ucchie79
FrieslandCampina Ingredients (Netherlands) is expanding its lactoferrin production capacity in its Veghel facility by 60 metric tons in 2022 to expand its early life nutrition and adult nutrition segments. This expansion will bring its total capacity to 70 mt per annum.
“Lactoferrin is a key ingredient in early life nutrition and has also shown potential health benefits for adults related to the immune system,” said Herman Ermens, president a.i. at FrieslandCampina Ingredients, in a press release. “Global demand for lactoferrin almost doubled between 2014 and 2019. By significantly expanding our production capacity, we can meet the needs of our customers. In addition, this investment exemplifies our strategy of growth through valued-added ingredients. Thanks to our technological leadership and unique experience, we’re perfectly placed to offer lactoferrin of the highest quality that complies with the strictest global regulatory requirements.”
Anne Peter Lindeboom, managing director early life nutrition at FrieslandCampina Ingredients, added: “FrieslandCampina was one of the first companies to start producing lactoferrin over 25 years ago. Today’s announcement shows we’re committed to identifying and investing in the ingredients that bring the best possible value for our customers.”
The company’s lactoferrin is 96% pure and directly extracted from raw milk. The product is spray dried and is recognized for its high consistency and excellent dry blending properties. To maintain these high standards, the expanded production location will feature state-of-the-art technology. In addition, the plant will use 100% green electricity.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.